Patents by Inventor Derek O'Hagan

Derek O'Hagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190262448
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Application
    Filed: March 7, 2019
    Publication date: August 29, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Luis BRITO, Andrew GEALL, Derek O'HAGAN, Manmohan SINGH
  • Publication number: 20190254968
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Application
    Filed: May 2, 2019
    Publication date: August 22, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis BRITO, Michelle C. ARCHER, Andrew GEALL, Derek O'HAGAN, Manmohan SINGH
  • Patent number: 10357568
    Abstract: To formulate amphiphilic pharmacological agents (in particular, amphiphilic immunopotentiators) in oil-in-water emulsions the invention provides an oil-in-water emulsion comprising an aqueous phase, an oil phase, a surfactant, and a phospholipid.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: July 23, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Patent number: 10333860
    Abstract: In accordance with a method a plurality of subscriber systems are provided, the systems being coupled via a Wide Area Network (WAN) and comprising a first subscriber system. The first subscriber system has processing and non-volatile storage and is suitably programmed for providing a subscriber service to a first subscriber. The first system is disposed in an unsecured location, which is associated with the first subscriber. Subsequently, the subscriber service is provided to the first subscriber. Separately, a task is provided to the first subscriber system via the WAN and is executed on the first subscriber system. An activity record for the execution of the task is logged, based on an amount of at least one of the processing and the non-volatile storage consumed on the first subscriber system during execution of the task.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: June 25, 2019
    Assignee: LEONOVUS USA
    Inventors: Daniel Willis, Paul Master, Gordon Campbell, Sean O'Hagan, Derek Noble
  • Publication number: 20190167786
    Abstract: A split influenza virus vaccine is adjuvanted with an oil-in-water emulsion that contains free surfactant in its aqueous phase. The free surfactant can continue to exert a ‘splitting effect’ on the antigen, thereby disrupting any unsplit virions and/or virion aggregates that might be present.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 6, 2019
    Inventor: Derek O'Hagan
  • Patent number: 10307374
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 4, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Michelle C. Archer, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 10286056
    Abstract: High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Publication number: 20190091329
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 28, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan
  • Patent number: 10238733
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 26, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Publication number: 20190083397
    Abstract: Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.
    Type: Application
    Filed: December 21, 2016
    Publication date: March 21, 2019
    Applicant: NOVARTIS AG
    Inventors: Ugo D'ORO, Luis BRITO, Derek O'HAGAN, Silvia VENDETTI
  • Patent number: 10183074
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 22, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 10149901
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: December 11, 2018
    Assignee: Seqirus UK Limited
    Inventors: Mario Contorni, Derek O'Hagan, Nicola Groth
  • Publication number: 20180318410
    Abstract: Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 8, 2018
    Inventors: Barbara BAUDNER, Derek O'HAGAN, Manmohan SINGH, Simone BUFALI
  • Patent number: 10112979
    Abstract: Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naïve to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: October 30, 2018
    Assignee: Seqirus UK Limited
    Inventor: Derek O'Hagan
  • Publication number: 20180280301
    Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.
    Type: Application
    Filed: May 16, 2018
    Publication date: October 4, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
  • Publication number: 20180256695
    Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Barbara BAUDNER, David A.G. SKIBINSKI, Manmohan SINGH, Derek O'HAGAN
  • Publication number: 20180250381
    Abstract: Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.
    Type: Application
    Filed: October 12, 2017
    Publication date: September 6, 2018
    Inventors: Derek O'HAGAN, Manmohan SINGH, Sung-Yun KWON
  • Patent number: 10046048
    Abstract: The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: August 14, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: David Skibinksi, Siddhartha Jain, Manmohan Singh, Derek O'Hagan
  • Publication number: 20180177871
    Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
    Type: Application
    Filed: February 26, 2018
    Publication date: June 28, 2018
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Barbara BAUDNER, Derek O'HAGAN, Manmohan SINGH, Simone BUFALI
  • Publication number: 20180169204
    Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Barbara BAUDNER, David SKIBINSKI, Manmohan SINGH, Derek O'HAGAN